Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas Donaldson

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Bioanalysis|December 13, 2019
Well-developed ligand-binding assays demonstrate robust performance using singlet analysisDouglas Donaldson, Shobha Purushothama, Eric David, et al.
Journal of Immunological Methods|August 25, 2016
Evaluation of highly sensitive immunoassay technologies for quantitative measurements of sub-pg/mL levels of cytokines in human serumDavid Yeung, Shawn Ciotti, Shobha Purushothama, et al.
Frontiers in Immunology|March 9, 2019
Effect of <i>in vivo</i> Hydroxychloroquine and <i>ex vivo</i> Anti-BDCA2 mAb Treatment on pDC IFNα Production From Patients Affected With Cutaneous Lupus ErythematosusAgnes Gardet, Alex Pellerin, Christie-Ann McCarl, et al.
Bioanalysis|June 20, 2020
Recommendations for singlet-based approach in ligand binding assays: an IQ Consortium perspectiveRenuka Pillutla, Boris Gorovits, Carol Gleason, et al.
Clinical & Translational Immunology|June 18, 2021
Next-generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cellsEris Bame, Hao Tang, Jeremy C Burns, et al.
Journal of Medicinal Chemistry|November 4, 2021
Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple SclerosisBrian T Hopkins, Eris Bame, Bekim Bajrami, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Bioanalysis|December 13, 2019
Well-developed ligand-binding assays demonstrate robust performance using singlet analysisDouglas Donaldson, Shobha Purushothama, Eric David, et al.
Journal of Immunological Methods|August 25, 2016
Evaluation of highly sensitive immunoassay technologies for quantitative measurements of sub-pg/mL levels of cytokines in human serumDavid Yeung, Shawn Ciotti, Shobha Purushothama, et al.
Frontiers in Immunology|March 9, 2019
Effect of <i>in vivo</i> Hydroxychloroquine and <i>ex vivo</i> Anti-BDCA2 mAb Treatment on pDC IFNα Production From Patients Affected With Cutaneous Lupus ErythematosusAgnes Gardet, Alex Pellerin, Christie-Ann McCarl, et al.
Bioanalysis|June 20, 2020
Recommendations for singlet-based approach in ligand binding assays: an IQ Consortium perspectiveRenuka Pillutla, Boris Gorovits, Carol Gleason, et al.
Clinical & Translational Immunology|June 18, 2021
Next-generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cellsEris Bame, Hao Tang, Jeremy C Burns, et al.
Journal of Medicinal Chemistry|November 4, 2021
Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple SclerosisBrian T Hopkins, Eris Bame, Bekim Bajrami, et al.
Pageof 1